Bayer's subsidiary AskBio received approval from the U.S. drug regulator to accelerate the development of its investigational gene therapy to treat moderate-stage Parkinson's disease.

AI helps scientists decode a cone snail toxin’s targets, paving the way for safer drug development and ecological research.

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

A new research paper was published by Aging (Aging-US) on January 8, 2025, in Volume 17, Issue 1, titled "Senolytic agent ABT-263 mitigates low- and high-LET radiation-induced gastrointestinal cancer ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

The cuts in funding to Cold Spring Harbor Laboratory are one of many being proposed to science and research centers across ...

Vanderbilt is one of several research universities nationally very concerned about cuts to NIH grant funding. We went inside on drug lab with a lead researcher to see exactly what is at stake.

Sunil Sharma, M.D., MBA, one of the nation’s leading experts in creating anti-cancer drugs, has been named director of ...

Around 1.5 million patients succumb to the disease caused by the bacterium Mycobacterium tuberculosis (Mtb). The novel ...

A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.